Home

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer.

More Info About Celyad ONCOLOGY

Latest News

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Celyad Oncology Provides Strategic Update

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

Celyad Oncology Announces Leadership Updates

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres-1

Celyad Oncology @celyadsa ·
21 Dec

Today we are providing an update on our strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property. Learn more about this announcement here: https://bit.ly/3Wy5FxV

Twitter 1605450385363292161
Celyad Oncology @celyadsa ·
10 Nov

We've just published our third quarter financial results and business updates- read more here: https://buff.ly/3NWjDH2 $CYAD

Twitter 1590684706021859328

View All

Stay informed about the latest news!

Sign up FOR our newsletter

    By clicking on “send”, you consent that your personal data will be processed by us in order to send you our newsletter. You have the right to access, rectify, erase your data, to restrict the processing and the right to withdraw your consent at any time. You can find more information on how we process your data in our Privacy Policy.